1 / 23

Cognitive Effects of Opioids in Persons with Chronic Non-Cancer Pain

Cognitive Effects of Opioids in Persons with Chronic Non-Cancer Pain. Scott Strassels, PharmD, BCPS scotts1@u.washington.edu 8/12/02 . Acknowledgments. Dr. Jim Robinson Dr. Dan Carr. Goal.

yeo-butler
Download Presentation

Cognitive Effects of Opioids in Persons with Chronic Non-Cancer Pain

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Cognitive Effects of Opioids in Persons with Chronic Non-Cancer Pain Scott Strassels, PharmD, BCPS scotts1@u.washington.edu 8/12/02 

  2. Acknowledgments • Dr. Jim Robinson • Dr. Dan Carr

  3. Goal • To review the current literature for studies of the effects of opioids on cognition, functioning, & health-related quality of life (HRQL) in persons with chronic, non-cancer pain

  4. Background • Opioids are associated with drowsiness, decreased ability to perform tasks, falls, difficulties with self-care (Medical Letter 2002;44(1134), Ebly EM et al 1997) • Effects are thought to be dose-dependent, to occur more often in elderly persons, & with drugs that have an active, renally-eliminated metabolite, such as meperidine) • Opioid use in elderly persons was associated with delirium in 3 of 5 prospective studies (Gray et al 1999) • 1 study grouped opioids with other psychoactive drugs

  5. Why is this important? • Important to policy makers, clinicians, & patients • Will this make me drowsy? • What can I take at work? • What are the implications for society & chances of treatment success?

  6. Methods • Literature search of Medline 1966 - present, Embase 1990 - 2002, PsycInfo 1887 – present, Cochrane Library 2002, Issue 2 • Search Terms: Opioid, cognitive, function, quality of life • Cancer, Substance abuse populations excluded

  7. Results • ~300 articles identified • Relatively few papers focus on the cognitive effects of opioids in persons with chronic, non-cancer pain

  8. McCracken et al 2001 • Prospective study to assess factors that best predict cognitive complaints • N = 275 consecutive patients, age  18 years, referred to a university pain management center • Excluded persons with history of head trauma or stroke • Participants may have had other types of brain impairment • Participants completed the Beck Depression Inventory (BDI), Pain Anxiety Symptom Scale (PASS), Sickness Impact Profile (SIP)

  9. McCracken et al 2001 (continued) • 54% reported  1 problem with cognitive functioning • Most common complaints: forgetfulness (23.4%), minor accidents (23.1%), difficulty finishing tasks (20.5%), difficulty with attention (18.7%) • Significantly associated with cognitive complaints: Use of antidepressants, pain severity, pain-related anxiety, & depression • No measure of perceived severity of cognitive functioning

  10. Sjøgren et al 2000 • Goal: To compare neuropsychological performance between chronic, nonmalignant pain patients on stable, long-term opioid therapy & healthy controls • N = 40, median age 60, 16 M, 24 F • Eligible persons: those taking opioids on a fixed time schedule, with a stable daily dose for  14 days • Excluded: users of other psychotropic drugs or alcohol, persons with metabolic disturbances, physical or neurological dysfunction interfering with the test

  11. Sjøgren et al 2000 (continued) • Opioids used: SR morphine, methadone, ketobemidone, buprenorphine, tramadol • Daily doses: 15-300 mg morphine (median = 60 mg) or equianalgesic doses of other opioids • Results were compared to 40 healthy, sex- & age-matched volunteers, met exclusion criteria • Testing was delayed for 50-450 minutes after the last dose, done late in the AM

  12. Sjøgren et al 2000 (continued) • Tests completed: Continuous Reaction Time (CRT), Finger Tapping Test (FTT), Paced Auditory Serial Audition Test (PASAT), Hospital Anxiety & Depression Scale (HAD), Karnofsky Performance Status Scale (KPS) • CRT measures attention/concentration, FTT measures psychomotor speed, & PASAT measures working memory

  13. Sjøgren et al 2000 (continued) • 38% of patients reported anxiety, 50% reported depression • Mean KPS = 70% (cares for self, unable to carry on normal activity or to do normal work • Physician completes the KPS instead of patient • Vigilance/attention, psychomotor speed, and working memory were significantly impaired in patients • Persons on methadone were significantly slower on the FTT using the dominant hand

  14. Sjøgren et al 2000 (continued) • Can’t tell if opioids were responsible for neuropsychological performance • Possible to compare to pain patients who were not using opioids?

  15. Zacny 1995 • Extensive review of published literature • Morphine • Speed of task performance slows temporarily, but tolerance develops • Accuracy of response, ability to process information, intellectual functioning appear to be less affected • Meperidine • Information is limited, with conflicting results • Anticholinergic effects may contribute to cognitive effects

  16. Zacny 1995 (continued) • Fentanyl, alfentanil • Task performance speed is more likely to be impaired than higher level cognitive processes (Digit substitution, learning, memory) • Methadone • At doses of 50-80 mg/day in people on methadone maintenance, published studies show inconsistent effects • Chronic pain patients on lower doses are unlikely to be adversely affected

  17. Zacny 1995 (continued) • Codeine • Doses are typically limited due to appearance of adverse effects • Doses used were no more than 50% of the standard analgesic dose of morphine • Even at low doses, some impairment was noted among healthy volunteers

  18. Zacny 1995 (continued) • Oxycodone, dihydrocodeine • Data on cognitive effects is limited • Oxycodone is increasingly important due to the popularity of Oxycontin • Oxycodone is approximately equipotent to morphine, thus effects might be expected to be similar

  19. Zacny 1995 (continued) • Propoxyphene • Motor response appears to be impaired, but not information processing • Unknown if tolerance develops • Long-acting active metabolite may contribute to effects

  20. Zacny 1995 (continued) • Conclusions • Overall, opioid users appear to show little if any impairment in laboratory tests • Epidemiological studies suggest no increased risk of accidents or impaired neuropsychological functioning • In healthy volunteers • Cognitive performance is less affected than psychomotor performance • Impairment is more apparent with agonist-antagonists and partial agonists

  21. Zacny 1995 (continued) • Concerns about cognitive effects are generally not a contraindication to chronic opioid therapy in persons with chronic, nonmalignant pain

  22. What’s Missing? • Research published in languages other than English • Effects of pain, opioid use on health-related quality of life

  23. Future Challenges • Separating the effects of disease & treatment • Understanding differences between types of injuries leading to chronic pain • How long do acute effects on cognition & functioning persist? • When does acute become chronic? • How do self-reported complaints correlate with neuropsychological test results & actual performance?

More Related